Most Viewed Articles - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Most Viewed Articles

GSK Divests OTC Brands Worth $264.7 Million

April 26, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

GlaxoSmithKline has reached an agreement to divest certain over-the-counter brands in selected territories to South Africa's Aspen Pharmacare Holdings for approximately $264.7 million.

Merck KGaA Announces Job Cuts

April 25, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

Merck KGaA has revealed further details about its previously announced restructuring program, including plans to eliminate approximately 580 jobs.

FDA Details Strategies for Addressing Globalization

April 23, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

A new report by FDA details the strategies, programs, and other activities the agency is using to address the rise of imported pharmaceutical products and APIs.

EMA Strengthens Oversight on Clinical Trials

April 19, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency (EMA) has published the final reflection paper concerning ethical and good clinical practice (GCP) aspects of clinical trials.

CDER Adds to Online Regulatory Learning Program

April 17, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

This month, CDER added a new program in drug safety to its "CDER World" platform for regulatory training and education.

Takeda to Acquire URL Pharma for $800 Million

April 16, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

Company makes bolt-on acquisition to enhance position in gout marketplace.

EMA Gets Tough on Conflicts of Interest

April 5, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

The management board of the European Medicines Agency has introduced a range of new measures to strengthen and extend its conflicts of interest policy for scientific-committee members and experts, as well as for members of the management board.

Ranbaxy Begins Shipping Generic Lipitor From Indian Facility

April 5, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

Ranbaxy Laboratories announced that beginning in March 2012, the first shipments of atorvastatin, the generic version of Pfizer's Lipitor, had been sent to US markets from its new Mohali manufacturing facility located in Punjab, India.

GPhA Urges Congress to Move Ahead on Generic-Drug and Biosimilar User Fees

April 5, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

On Mar. 29, 2012, the Generic Pharmaceutical Association reiterated its call for Congress to move forward with user-fee proposals for generic drugs and biosimilar products.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Click here